Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
In development
Reference number: GID-TA11221
Expected publication date: TBC
Following discussions with the company, NICE has agreed to hold a second draft guidance consultation and return for a third committee discussion to consider additional data.